This is a preview of subscription content, log in via an institution to check access.
References
Tefferi A, Skoda R, Vardiman JW . Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 2009; 6: 627–637.
Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in tet2 in myeloid cancers. N Engl J Med 2009; 360: 2289–2301.
Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905–911.
Beer PA, Delhommeau F, Lecouedic JP, Dawson MA, Chen E, Bareford D et al. Two routes to leukemic transformation following a jak2 mutation-positive myeloproliferative neoplasm. Blood 2010; 115: 2891–2900.
Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A et al. Clonal analysis of tet2 and jak2 mutations suggests that tet2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010; 115: 2003–2007.
Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065–3072.
Dupont S, Masse A, James C, Teyssandier I, Lecluse Y, Larbret F et al. The jak2 617v>f mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 2007; 110: 1013–1021.
Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27: 5418–5424.
Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I et al. A common jak2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009; 41: 450–454.
Acknowledgements
This work received funding from the MPD foundation, the Association Laurette Fugain, the Fondation de france and the Institut National du Cancer. This work was supported by grants from the Ligue Nationale Contre le Cancer (équipe labelisée 2009). This letter is dedicated to Sabrina Dupont whose work greatly contributed to the discovery of TET2 mutations in MPNs.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Kiladjian, JJ., Massé, A., Cassinat, B. et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia 24, 1519–1523 (2010). https://doi.org/10.1038/leu.2010.120
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.120
- Springer Nature Limited
This article is cited by
-
Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis
International Journal of Hematology (2021)
-
Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions
International Journal of Hematology (2020)
-
Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Seminars in Immunopathology (2019)
-
Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone
Leukemia (2016)
-
EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia
Journal of Cancer Research and Clinical Oncology (2016)